Interest for Raptor Pharmaceuticals is really picking up in 2011. Here are the recent headlines for this up and coming Small Cap Pharmaceutical company. It has a Pipeline for Rare Diseases and I expect 2011 to be a strong year for Raptor Pharmaceuticals if Clinical Trial results are successful. Results for DR Cysteamine clinical trials is expected in 1Q 2011. DR Cysteamine has clinical development programs including:
◦Nephropathic Cystinosis, a rare genetic disorder (Phase 3)
◦Non-alcoholic Steatohepatitis (NASH), a metabolic disorder of the liver (Phase 2)
◦Huntington's Disease, an inherited neurodegenerative disease (Phase 2)
Raptor Pharmaceuticals Stock Quote: RTTP Google Finance
Read more from their previous 10-K filings for the company's Strategic Development Plan here.
Find out more about their Clinical Pipeline here.
Continued
Showing posts with label Cystinosis. Show all posts
Showing posts with label Cystinosis. Show all posts
Subscribe to:
Posts (Atom)